Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Lytixar (LTX-109) for uncomplicated Gram-positive skin infections and mild eczema/dermatoses; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lytixar (LTX-109)

Snippet

Sponsor: Lytix Biopharma AS | Conditions: Gram-positive, Skin Infections, Mild Eczema/Dermatoses | Phase 2 | Status: COMPLETED